Market Cap
$20.4B
VTRS
Viatris Inc
$17.60 ▲ +0.80%
Prev close $17.46Market cap$20.4B
ConsensusBuy
12-mo target$19.40 (+10.2%)
▲ Bullish
Analyst conviction 7/10
High Impact Filing (7/10)28 New Institutional Positions22 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on VTRS right now — valuation, ownership and activity at a glance.
Cap Size
Large Cap
Analyst Consensus
Buy (65%)
Inst. Holders
50 funds
Inst. Value
$12.6B
Inst. Activity
28 buys / 22 sells
Insider Activity
$0.00 buy / $1.1M sell
Insider Net $
-$1.1M
SEC Reports
12
Price chart 30d +3.9%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Dec 27, 2026 fda_pdufa
PDUFA: VTRS — MR-107A-02 (fast-acting meloxicam) in moderate-to-severe acute pain — 2026-12-27
FDA target action date 2026-12-27 for VTRS (Viatris Inc). Drug: MR-107A-02 (fast-acting meloxicam).
Sep 9, 2026 Event
Carton label: Mycophenolate Mofetil for injection, USP, 500 mg/vial, Sterile, 4 Single Dose Vials, Rx only, Manufactured for: Mylan Institutional LLC, Morgantown, WV 26505, Made in India, NDC 67457-386-81. Vial Label: Mycophenolate Mofetil for injection, USP, 500 mg/vial, Sterile, Single Dose Vial, Rx only, Manufactured for: Mylan Institutional LLC, Morgantown, WV 26505, Made in India, NDC 67457-386-00.
Class II: Failed Dissolution Specifications
Aug 15, 2026 Insider
Enrietti Andrew acquired via exercise 25,134 shares
See Remarks
Aug 15, 2026 Insider
Enrietti Andrew acquired via exercise 999 shares
See Remarks
Aug 15, 2026 Insider
Aug 6, 2026 SEC Enrietti Andrew acquired via exercise 998.364 shares
See Remarks
Viatris Q2 2026 earnings beat consensus with adjusted EPS of $0.69 (15% above $0.60 est) and total revenue of $3.76B (+5
8-K — Impact 7/10
Aug 3, 2026 Event
Jul 3, 2026 SEC LU v. VIATRIS SPECIALTY, LLC d/b/a VIATRIS MEDICAL UNIT
Court ruling (njd) — Docket: 2:25-cv-16431
The District of New Jersey denied plaintiff's motion to vacate the prior dismissal of a product liability/consumer fraud
COURT-RULING — Impact 2/10
Analyst ratings buy % +16.1%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
65% rate it Buy or better · 17 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Sep 23, 2026 | Oppenheimer | INITIATE | Outperform | 52% |
| Sep 16, 2026 | Piper Sandler | MAINTAIN | Neutral | 54% |
| Sep 9, 2026 | Leerink Partners | INITIATE | Outperform | 49% |
| Sep 8, 2026 | Argus Research | MAINTAIN | Buy | 54% |
| May 19, 2026 | Barclays | MAINTAIN | Overweight | 54% |
| May 8, 2026 | JP Morgan | MAINTAIN | Neutral | 55% |
| May 8, 2026 | Truist Securities | MAINTAIN | Buy | 55% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 4 | 7 | 5 | 1 | 0 | 65% | |
| Aug 1, 2026 | 4 | 7 | 5 | 1 | 0 | 65% | |
| Jul 1, 2026 | 4 | 7 | 5 | 1 | 0 | 65% | |
| Jun 1, 2026 | 4 | 8 | 5 | 1 | 0 | 67% | |
| May 1, 2026 | 4 | 8 | 5 | 1 | 0 | 67% | |
| Apr 1, 2026 | 4 | 8 | 5 | 1 | 0 | 67% | |
| Mar 1, 2026 | 4 | 8 | 5 | 1 | 0 | 67% | |
| Feb 1, 2026 | 4 | 7 | 5 | 2 | 0 | 61% |
Price targets
Where 10 covering analysts think VTRS trades over the next 12 months.
$19.40 +10.2% upside Buy
Current$17.60 Low$13.00 Median$20.00 High$25.00 10 analysts
$13.00$25.00
Analyst rating Buy· 2.0/5 as of Oct 2, 2026
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
12 SEC filing reports analyzed · 4 bullish, 1 bearish, 2 mixed, 5 neutral · avg impact 4.8/10.
BULLISH8-K7/10
Viatris Q2 2026 earnings beat consensus with adjusted EPS of $0.69 (15% above $0.60 est) and total r
Aug 6, 2026
NEUTRALCOURT-RULING2/10
The District of New Jersey denied plaintiff's motion to vacate the prior dismissal of a product liab
Jul 3, 2026
BULLISHCOURT-RULING4/10
The District Court of New Jersey denied plaintiff Norton's motion to vacate the dismissal of her pro
Jul 3, 2026
MIXEDCOURT-RULING6/10
The District Court of New Jersey adopted a Special Master's recommendation to partially grant Teva's
Jul 3, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Dec 27, 2026
fda_pdufa
PDUFA: VTRS — MR-107A-02 (fast-acting meloxicam) in moderate-to-severe acute pain — 2026-12-27
FDA target action date 2026-12-27 for VTRS (Viatris Inc). Drug: MR-107A-02 (fast-acting meloxicam). Indication: moderate-to-severe acute pain. FDA ass
Oct 17, 2026
fda_pdufa
PDUFA: VTRS — MR-141 in presbyopia — 2026-10-17
FDA target action date 2026-10-17 for VTRS (Viatris Inc). Drug: MR-141. Indication: presbyopia. PDUFA goal date for MR-141 (phentolamine ophthalmic so
Oct 2, 2026
Clinical Trial
A Research Study to Evaluate the Efficacy and Safety of Cenerimod in Subjects Suffering From Systemic Lupus Erythematosus
Phase Phase 3 — ACTIVE_NOT_RECRUITING
Oct 2, 2026
clinical_trial_readout
T-90d Trial Readout: Cenerimod (Phase 3)
Trial: A Research Study to Evaluate the Efficacy and Safety of Cenerimod in Subjects Suffering From Systemic Lupus Erythematosus Sponsor: Viatris Inno
Oct 1, 2026
Clinical Trial
Ketoprofen Topical Patch 20% in the Treatment of Pain Associated With Shoulder, Elbow or Knee Tendonitis or Bursitis
Phase Phase 3 — COMPLETED
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $0.64 | $0.61–$0.69 | -3.7% | -0.8% | 3↑ 3↓ | $3.8B | 10 |
| Next Q | $0.59 | $0.55–$0.64 | 3.6% | +1.3% | 1↑ 5↓ | $3.7B | 10 |
| Current FY | $2.52 | $2.47–$2.58 | 7.1% | +0.7% | 5↑ 0↓ | $14.8B | 11 |
| Next FY | $2.67 | $2.59–$2.80 | 6.2% | +0.2% | 3↑ 3↓ | $15.0B | 11 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $0.645 | — |
| 7d ago | $0.648 | -0.003 |
| 30d ago | $0.650 | -0.005 |
| 60d ago | $0.641 | +0.004 |
| 90d ago | $0.650 | -0.005 |
Institutional ownership
Which big funds own VTRS (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $12.6B total value (790,348,331 shares) as of 2026-Q2. Top holders: FMR, BlackRock,, VANGUARD. Net buying activity: 28 institutions added/increased vs 22 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| FMR LLC | 96,662,102 | $1.5B | 12.2% | DOUBLED +482.7% |
| BlackRock, Inc. | 86,019,468 | $1.4B | 10.9% | — |
| VANGUARD CAPITAL MANAGEMENT LLC | 76,046,939 | $1.2B | 9.6% | — |
| DAVIS SELECTED ADVISERS | 75,232,254 | $1.2B | 9.5% | — |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 54,282,080 | $862.0M | 6.9% | — |
| STATE STREET CORP | 53,069,461 | $842.7M | 6.7% | — |
| Rubric Capital Management LP | 34,168,743 | $542.6M | 4.3% | — |
| GEODE CAPITAL MANAGEMENT, LLC | 32,807,906 | $520.1M | 4.1% | — |
| DIMENSIONAL FUND ADVISORS LP | 29,970,094 | $476.0M | 3.8% | — |
| Invesco Ltd. | 20,771,275 | $329.8M | 2.6% | — |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| FMR LLC | DOUBLED | 16,588,514 | 96,662,102 | +482.7% | $1.5B |
| JPMORGAN CHASE & CO | ADD | 5,731,565 | 7,322,267 | +27.8% | $119.7M |
| Qube Research & Technologies Ltd | TRIM | 9,666,750 | 6,180,223 | -36.1% | $98.1M |
| UBS Group AG | ADD | 3,257,531 | 6,092,296 | +87.0% | $96.7M |
| JANE STREET GROUP, LLC | DOUBLED | 2,192,665 | 5,569,311 | +154.0% | $88.4M |
| Assenagon Asset Management S.A. | DOUBLED | 783,134 | 4,989,006 | +537.1% | $79.2M |
| NORGES BANK | NEW | — | 3,822,744 | — | $60.7M |
| RHUMBLINE ADVISERS | ADD | 1,941,082 | 2,872,464 | +48.0% | $45.6M |
| Allianz Asset Management GmbH | DOUBLED | 550,739 | 2,485,117 | +351.2% | $39.5M |
| FIL Ltd | TRIM | 2,886,622 | 2,118,598 | -26.6% | $33.6M |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
16 insiders, 50 transactions. Net -$1.1M — $0.00 bought, $1.1M sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Aug 15, 2026 | Enrietti Andrew | See Remarks | EXERCISE | 25,134 | — | — |
| Aug 15, 2026 | Enrietti Andrew | See Remarks | EXERCISE | 999 | — | — |
| Aug 15, 2026 | Enrietti Andrew | See Remarks | EXERCISE | 998.364 | — | — |
| Aug 15, 2026 | Enrietti Andrew | See Remarks | TAX W/H | 435 | $16.23 | $7.1K |
| Aug 15, 2026 | Enrietti Andrew | See Remarks | TAX W/H | 10,931 | $16.23 | $177.4K |
| Jun 30, 2026 | Groothuis Leo Frans | Director | AWARD | 2,756 | $15.88 | $43.8K |
| Jun 30, 2026 | SIMMONS DAVID S | Director | AWARD | 2,362 | $15.88 | $37.5K |
| Jun 25, 2026 | Campbell Paul | See Remarks | SELL | 50,076 | $16.17 | $809.8K |
| Apr 15, 2026 | Le Goff Corinne | Chief Commercial Officer | EXERCISE | 39,344 | — | — |
| Apr 15, 2026 | Le Goff Corinne | Chief Commercial Officer | TAX W/H | 17,450 | $13.86 | $241.9K |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for VTRS.
Shares short
40,790,228
Settlement Sep 15, 2026
Change vs prior
+5.6%
Semi-monthly cycle
Days to cover
5.6
At avg daily volume
Of shares outstanding
≈3.5%
Estimate — not % of float
All VTRS filing & press-release reports (12)
- 8-K reportAug 6, 2026
- COURT-RULING reportJul 3, 2026
- COURT-RULING reportJul 3, 2026
- COURT-RULING reportJul 3, 2026
- COURT-RULING reportJul 3, 2026
- 144 reportJun 26, 2026
- 8-K reportJun 19, 2026
- 8-K reportJun 15, 2026
- COURT-RULING reportMay 13, 2026
- 8-K reportMay 7, 2026
- 8-K reportMay 4, 2026
- 8-K reportFeb 26, 2026